A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Screpanti, Emanuela ^a   Santaguida, Stefano ^a   Nguyen, Tam ^b   Silvestri, Romano ^c   Gussio, Rick ^b   Musacchio, Andrea ^a   Hamel, Ernest ^b   de Wulf, Peter ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 FURAN 2 YL 3 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 1H INDOLE 2 CARBOXYLIC ACID DERIVATIVE; 6 FURAN 2 YL 3 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 1H INDOLE 2 CARBOXYLIC ACID TETRAHYDROFURAN 2 YLMETHYL ESTER; ALPHA TUBULIN; ANTIMITOTIC AGENT; BETA TUBULIN; COLCHICINE; COMBRETASTATIN A4; NDC80 COMPLEX; NOCODAZOLE; TUBULIN MODULATOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NDC80 PROTEIN, HUMAN; NUCLEAR PROTEIN; RECOMBINANT PROTEIN; TUBULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL INTERACTION; CENTROMERE; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; MICROTUBULE; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; CELL SURVIVAL; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GENETICS; HELA CELL; METABOLISM; TUMOR CELL LINE;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HELA CELLS; HUMANS; KINETOCHORES; MICROSCOPY, FLUORESCENCE; MICROTUBULES; NUCLEAR PROTEINS; PROTEIN BINDING; RECOMBINANT PROTEINS; TUBULIN;

EID: 77955407826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011603     Document Type: Article

References (23)

1. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348.
2. Morgan DO (2007) The cell cycle: principles of control (Primers in biology). London: New Science Press Ltd. 297 p.
3. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nature Rev Cancer 4: 253-265.
4. Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8: 379-393.
5. Gascoigne KE, Taylor SS (2009) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111-122.
6. Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity and resistance. Mol Cancer Ther 8: 2086-2095.
7. Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7: 107-117.
8. Carlson RO (2008) New tubulin targeting agents currently in clinical development. Expert Opin Invest Drugs 17: 707-722.
9. Liu S-T, Yen TJ (2008) The kinetochore as a target for cancer drug development. In: De Wulf P, Earnshaw WC, eds. The kinetochore: from molecular discoveries to cancer therapy. New York: Springer Publ. pp 455-479.
10. Ciferri C, Musacchio A, Petrovic A (2007) The Ndc80 complex: hub of kinetochore activity. FEBS Lett 581: 2862-2869.
11. Cao TM, Durrant D, Tripathi A, Liu J, Tsai S, et al. (2008) Stilbene derivatives that are colchicine site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. Am J Hematol 83: 390-397.
12. Ciferri C, Pasqualato S, Screpanti E, Varetti G, Santaguida S, et al. (2008) Implications for kinetochore-microtubule attachment from the structure of an engineered Ndc80 complex. Cell 133: 427-439.
13. Gaskin F, Cantor CR, Shelanski ML (1974) Turbidimetric studies of the in vitro assembly and disassembly of porcine neurotubules. J Mol Biol 89: 737-758.
14. Hamel E (2003) Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys 38: 1-21.
15. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198-202.
16. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, et al. (2005) A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 48: 6107-6116.
17. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, et al. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435: 519-522.
18. Bhattacharya B, Wolff J (1977) Maytansin binding to the vinblastin sites of tubulin. FEBS Lett 75: 159-162.
19. Wood KW, Lad L, Luo L, Qian X, Knight SD, et al. (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Si USA 107: 5839-5844.
20. Kang GJ, Getahun Z, Muzaffar A, Brossi A, Hamel E (1990) N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. Evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem 265: 10255-10259.
21. Hamel E, Lin CM (1981) Stabilization of the colchicine-binding activity of tubulin by1organic acids. Biochim Biophys Acta 675: 226-231.
22. Parodi B, Aresu O, Bini D, Lorenzini R, Schena F, et al. (2002) Species identification and confirmation of human and animal cell lines: a PCR based method. Biotechniques 32: 432-440.
23. Uphoff CC, Drexler HG (2002) Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. In Vitro Cell Dev Biol Anim 38: 79-85.